Back to News
Market Impact: 0.35
Lakefront Biotherapeutics Targets 2027 Registrational Trials for Gamgertamig
Source: marketbeat.com
Healthcare & BiotechM&A & RestructuringCorporate Guidance & Outlook
Lakefront Biotherapeutics plans to begin registrational studies in 2027 for gamgertamig, its lead T-cell engager. The development follows a broad restructuring of its legacy cell-therapy business and the acquisition of assets from Ouro Medicines, repositioning the company around its clinical-stage oncology pipeline.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.30
Ticker Sentiment
LKFT0.45
More News
- Tech stock rout, driven by US AI fears, continues in Asian trading
- Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction
- RIP the Cybertruck: Elon Musk says Tesla will wind down production of its most polarizing EV
- Tesla will stop making the Cybertruck in 2027
- Tesla is 'winding down' Cybertruck production at its Texas Gigafactory
- Cloudflare posts its fastest growth in nearly 4 years and lifts its outlook